Exenatide is an analog of the incretin hormone glucagon-like peptide (GLP-1) that is used for the treatment of T2D for their metabolic effects. In addition to its insulinotropic effects, exenatide increases functional islet mass and improves their survival. Improved outcomes have been reported in recent clinical islet transplantation trials for the treatment of type 1 diabetes. The purpose of this study was to investigate whether exenatide has anti-inflammatory properties in human islets. Exenatide treatment improved islet function, significantly reduced content of inflammation-related molecules (tissue factor, IFN-γ, IL-17, IL-1β, and IL-2) and caspase 3 activation, whereas increased phosphorylation of ERK1/2, STAT3, and Akt in vitro.
INTRODUCTION
in patients with brittle T1D (22,28,36,52). GLP-1R stimulation produces direct effects on β-cells, resulting in proliferation, increased cell regeneration, and reduced One of the major incretin hormones is the glucagonlike peptide-1 (GLP-1). GLP-1 is secreted in response cell apoptosis in animal models, isolated human islets, and β-cell lines (29, 35, 67) . Whether the improvements to oral nutrient ingestion and acts enhancing glucosedependent stimulation of insulin secretion. GLP-1 also observed in clinical studies are the direct effects of GLP-1 agonists on β-cell function or are a result of improved controls blood sugar via inhibition of glucagon secretion and reduction in gastric emptying (23). The biological glycemic control remains to be elucidated. Recent studies have correlated long-term treatment half-life of GLP-1 is very short (2 min) (20,61), as it is degraded by the ubiquitous enzyme dipeptidyl peptidase with exenatide with acute pancreatitis (4, 19) . However, additional clinical trial data and in-depth case report IV (DPP-IV) (20). GLP-1 mimetics and incretin enhancers (DPP-IV inhibitors) are a new class of drugs used for the analysis are needed to further evaluate and verify this finding (3). treatment of type 2 diabetes (T2D). Exendin-4, a peptide isolated from the Gila Monster's (Heloderma suspecPrevious studies described anti-inflammatory effects of exenatide in different contexts. In adipocytes, exenatum) saliva, shares about 50% sequence homology to GLP-1. It is a potent agonist for the GLP-1 receptor and tide induces the expression of adiponectin and simultaneously inhibits proinflammatory adipokines (46) . In an stable against DPP-IV (26). A synthetic exendin-4 (exenatide; Amylin Pharmaceuticals, CA) has been used animal model of Parkinson's disease, exenatide protects dopaminergic neurons suppressing expression of tumor for the treatment of T2D since 2005 (10, 14) . The cytoprotective properties of GLP-1 mimetics (29,39) suggest necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) (47) . Likewise, exenatide confers cytoprotection to that they may also be beneficial for islet transplantation β-cell lines and pancreatic islets against proinflammah (preincubation period) and then sequentially stimulated with 3 (5 min), 11 (10 min) , and 3 mM glucose tory cytokines such as IL-1β in vitro (30, 43, 63, 64) .
The purpose of our study was to characterize the anti-(15 min), respectively, and then with 25 mM KCl (5 min) followed by 3 mM glucose (5 min). Fractions of inflammatory properties of exenatide in human islets. Herein we report that exenatide treatment is associated the perifusates were collected every second minute during the preincubation phase, and every minute during with the reduction of cytokines and tissue factor (TF) production by islets in vitro. Furthermore, we report that stimulation (13) . Human insulin concentrations were determined in the collected perifusates by ELISA exenatide treatment increases the expression of the serine proteinase inhibitor-9 (PI-9; Serpin B9) (8) collected and TF concentration was quantitatively determouse pancreata by collagenase digestion and purificamined in the supernatant using the IMUBIND Tissue tion on density gradients and then cultured in CMRL Factor ELISA Kit (American Diagnostica). Data were 1066-based medium (Gibco-Invitrogen). All animal procorrected for protein content. cedures were performed under protocols reviewed and approved by the University of Miami IACUC (LaboraDetermination of Protein Phosphorylation tory Animal Welfare Assurance #A-3224-01).
Cultured human and mouse islets treated or not with Exenatide Treatment exenatide were harvested at selected time points in lysis buffer and stored until assayed. Phosphorylated and total Human islets were cultured at 37°C, 5% CO 2 humidified ambient in CMRL-based Miami modified medium content of AKT (Ser473), extracellular signal-regulated kinase 1 (ERK1/2) (Thr185/Tyr187), p38 mitogen-acti-1 (MM1; Mediatech), containing 5 mM glucose and supplemented with 2% human serum albumin. Mouse islets vated protein kinase (p38 MAPK) (Thr180/Tyr182), cJun (Ser63), cJun N-terminal kinases (JNK) (Thr183/ were cultured in supplemented CMRL containing 10% heat-inactivated fetal bovine serum (56) . Human islets Tyr185), and Iκβ (Ser32/Ser36) were quantitatively determined using the BioPlex platform (Bio-Rad), as were treated with exenatide (0.0, 0.1, 1, 10, and 100 nM) within 2 h from isolation. Akt phosphorylation was meadescribed (32 goat anti-mouse 568; goat anti-rabbit 488; goat antiwere calculated via SDS software as previously described (49). RQ represents the ratio of expression of guinea pig 647 (Invitrogen, dilution 1:400). Nucleus was detected by DAPI staining (Invitrogen). After final PI-9 transcripts over the expression of the housekeeping gene β-actin. RT and PCR were done in triplicate using washes, slides were mounted using vectashield. Images were acquired by confocal microscopy and compiled RT universal or specific primers and PCR-specific probes for each gene of interest (Applied Biosystems).
using Photoshop 7.0. Only contrast and brightness were altered for visualization purposes.
Role of the Protein Kinase A (PKA) Pathway on PI-9 Statistical Analysis Upregulation Induced by Exenatide
Unless otherwise stated, all experiments were perHuman islets were preincubated for 1 h with the selecformed at least three times. Differences between experitive inhibitor of PKA, H89 (100 nM, Tocris Bioscience, mental conditions yielding p < 0.05 were considered MO), or vehicle. After the preincubation period, islets statistically significant. According to the number of facwere stimulated either with 10 nM exenatide or forskolin tors/variables, a paired t-test or ANOVA were used for (FRSK 10 mM, Sigma) for 4 h. Samples were collected the calculations, with the SigmaStat software selecting and stored at −80°C for further analysis by RT-PCR.
the appropriate post hoc test where necessary.
In Vivo Effects of Exenatide on Human Islet Grafts

RESULTS
Athymic nu/nu (nude) mice were purchased from
Exenatide Has Anti-Inflammatory Properties Harlan (Indianapolis, IN) and housed in microisolated cages with free access to autoclaved food and water in Human islets are generally kept in culture for about 48-72 h prior to transplantation. During this time, an virus antibody-free rooms in the Department of Veterinary Resources at the University of Miami. Under genestimate of about 30% islet loss is generally observed that is paralleled by a release of proinflammatory cytoeral anesthesia (isoflurane 2% mixed with oxygen), human islet aliquots of ϳ1,000 IEQ were implanted kines (41, 48) . Furthermore, these molecules may contribute to increased islet immunogenicity. We observed under the kidney subcapsular space. Treatment consisted of intraperitoneal injection via an osmotic pump (Alzet, that treatment with exenatide reduced the levels of IL-1β, IL-2, IL-17, and interferon-γ (IFN-γ) in human islet model #2001, infusion rate 1 µl/h) of either phosphatebuffered saline (PBS) or exenatide (3 µg/day). Animals supernatants after 48 h of culture (Table 1) . Although there was a trend already at 12 and 24 h, we didn't were humanely sacrificed 24 h after transplantation. Grafts were retrieved for molecular studies and stored observe a statistically significant effect of exenatide in islets before 48 h, perhaps reflecting the time that is necfrozen at −80°C until assayed.
essary to secrete sufficient amount of cytokines into the Immunofluorescence media for accurate quantification. To further investigate which cell is involved in the production of cytokines we Pancreatic specimens were collected and fixed in 4% (w/v) paraformaldehyde in 0.1 M phosphate buffer, pH performed immunostaining for IL-1β, insulin and glucagon. The result showed that human β-, but not α-cells 7.4, for 30 min at 4°C, dehydrated in increasing concentrations of alcohol, and embedded in paraffin. Antibodies colocalize with IL-1β (Fig. 1A) . We also observed that GLP-1R is expressed in human β-cells but not in α-cells were used at the following dilutions: rabbit polyclonal anti-human GLP-1R (1:50, Santa Cruz Biotechnolog- (Fig. 1B) . We did not observe differences in the GLP1-R and IL-1β expression by immunostaining when islets ies); rabbit anti-human glucagon (1:250, Dako); guinea were treated with exenatide 10 nM for 24 h (data not ERK1/2 phosphorylation was also increased upon treatment with exenatide. Although the lowest dose seemed shown). Thus the differences in IL-1β between control and exenatide-treated islets were only detectable by less effective, there was no statistical difference between the doses studied (Fig. 3C) . The time course for ERK1/ direct cytokine assessment.
A phenomenon defined as "instant blood-mediated 2 activation exhibited a distinct profile with maximum activation occurring at 24 h (data not shown). inflammatory response" (IBMIR) has been implicated in the early loss of functional islets that occurs after intra-
STAT3 Phosphorylation Is Increased in the Presence hepatic islet transplantation (5). This phenomenon has
of Exenatide been associated with TF production, which is expressed in isolated islets (6) . Our results showed that treatment Recent data suggest a cytoprotective role for the with exenatide reduced TF content in human islets fol-STAT3-SOCS3 (suppressor of cytokine signaling 3) lowing 48 h of culture (Fig. 2) .
pathway in rat pancreatic islets (59) . Neonatal rat islets treated with ciliary neurotrophic factor (CNTF) signal Phosphorylation Levels of Inflammation/ through STAT3 pathway inhibiting caspase-3 activation Death-Related Kinases Remain Constant induced in the presence of cytokines. We investigated Upon Stimulation With Exenatide the effects of different concentrations of exenatide in STAT3 phosphorylation in cultured human islets. Our Previous studies show that exenatide downregulates results showed that exenatide increased STAT3 phosinflammation/death-related kinases in islets under cytophorylation in human islets (Fig. 4A) . Likewise, we toxic conditions (30,45). We studied its ability to moduobserved that caspase-3, which is activated upon islet late the phosphorylation of a panel of stress-activated culture (51), was reduced upon treatment with exenatide protein kinases (namely, cJUN, JNK, p38, and Iκβ) in (Fig. 4B) . In addition, we tested whether exenatide cultured human islets. The phosphorylation status of affects human islets function by measuring the glucosethese kinases was not significantly reduced in our study mediated insulin secretion in dynamic perifusion assays after 24 h of treatment with 10 nM exenatide (Fig. 3A) . (Fig. 5) . After 48 h of treatment with exenatide, islets It has been reported that exenatide increases Akt and were perifused and the insulin content assessed in the ERK1/2 phosphorylation in islet cells, which parallel perifusate. Four out of six experiments showed that improved cell viability in vitro (9, 55) . To evaluate both exenatide could enhance islet function in a dose-depentime course and dose-response to exenatide, human dent manner. islets were treated with increasing doses of exenatide and the primary endpoint assessed was Akt phosphorylaExenatide Induces Sustained and Dose-Dependent PI-9 tion changes. The lowest dose studied (0.1 nM) was sufUpregulation in Human Islets ficient to induce a statistically significant increase in Akt phosphorylation, when compared to control islets (Fig. The serine proteinase inhibitor PI-9 can protect target cells from the attack of cytotoxic T lymphocytes and 3B). When a time course study was performed, treatment with exenatide 10 nM increased Akt phosphorylanatural killer cells (7, 18, 42) . Our preliminary screening of inflammation-related molecules led to the novel findtion within 1 h and was sustained for up to 24 h before decreasing (about 20%) by 48 h (data not shown).
ing that exenatide induced an increase in PI-9 expression in human islets in culture. Treatment of human islets The results show that PI-9 is mainly expressed in β-cells (Fig. 7) . with 10 nM exenatide for 24 h induced more than twofold increase in PI-9 expression. Dose-response for Exenatide-Induced PI-9 Upregulation Is Mediated exenatide (0, 0.1, 1, 10, and 100 nM) and time course by cAMP studies were performed to determine the optimal culture conditions to attain a maximal anti-inflammatory effect
We investigated the effect of cAMP, a critical second messenger mediating GLP-1 analogues effects, in the on human islets. Twenty-four-hour exenatide treatment resulted in increased PI-9 content in a dose-dependent induction of PI-9 expression. We observed an increase of PI-9 expression in islets treated with the cAMP rising manner (Fig. 6A ). The minimal dose at which PI-9 was induced was 0.05 nM (data not shown). Exenatide 10 agent forskolin (Fig. 8) , while an opposite effect was found when the islets were treated with exenatide in the nM increased PI-9 expression within 1 h and the effect was sustained for 48 h (Fig. 6B) . A similar sustained presence of the PKA inhibitor H89. upregulation of PI-9 mRNA steady-state level was
Exenatide Upregulates PI-9 Expression in Human Islet detected also in murine islets exposed to exenatide for Grafts In Vivo 48 h in vitro (data not shown). PI-9 overexpression was also induced in human islets by GLP-1, although to a We sought to further investigate whether PI-9 upregulation could be induced by exenatide in vivo in human lesser degree than with exenatide. Exenatide-mediated PI-9 expression was partially blocked by exendin-9, an islets transplanted into immunodeficient mice. Untreated human islets were transplanted under the kidney capsule antagonist of the canonical GLP-1R (37) (Fig. 6C) . Notably, exendin-9 by itself also slightly increases the of nude mice receiving either saline (control) or exenatide via an intraperitoneal osmotic pump (3 µg/day). The level of PI-9 expression.
grafts were harvested 24 h after transplantation (n = 4 PI-9 Is Expressed in Human β-Cells islet grafts/experimental condition) for RT-PCR analysis of PI-9. Control, nontransplanted islet aliquots from the To assess which cell type expresses PI-9, we conducted immunostaining in freshly isolated human islets.
same human islet preparations were used to determine basal levels of expression. Our results indicate that in glucagon, insulin and IL-1β that showed colocalization of IL-1β with insulin-positive but not with glucagonvivo treatment with exenatide is associated with an increase in PI-9 expression in human islet grafts when positive cells. Notably, we did not observe IL-1β in other islet cell types (Fig. 1A) . In another set of expericomparing to control grafts (Fig. 9) . ments, and in agreement with previous report (65), we DISCUSSION found that insulin, but not glucagon, colocalized with GLP-1R (Fig. 1B) . These observations suggest that Proinflammatory cytokines, such as IL-1β, IFN-γ, and TNF-α, play a critical role in the pathophysiology exenatide may preclude IL-1β secretion by activating GLP-1R in the human β-cells. GLP-1R was also of type 1 diabetes (21, 24, 38) . Isolated islets produce proinflammatory cytokines during the early postisolation expressed in islet cells not stained for insulin. TF expression in islets is believed to be one of the major culture period as a consequence of the activation of stress signal transduction pathways resulting from pantriggers of IBMIR (5). We observed that TF content in human islets is reduced by 30% upon 48 h treatment creas ischemia, islet isolation process, and culture conditions (2, 12, 31, 32, 53, 54, 57, 62) . In order to elucidate the with exenatide in culture (Fig. 2) . After 48 h the plateau of inhibition was reached even with the smallest dose possible mechanisms involved in the increased survival and function of islets treated with exenatide, we investistudied (0.1 nM), which is close to the levels found in humans treated with exenatide. gated its effects on basal secretion of cytokines by freshly isolated human islets in culture and observed that Signaling molecules such as JNK, p38, NF-κB, and cJUN mediate death-related events including those trigexenatide significantly diminishes human islet production of IL-1β and IFN-γ by 30% and 45%, respectively. gered by cytokines in islet cells (1, 11, 16, 24, 30) . In fact, selective inhibition of JNK phosphorylation in human Using immunohistochemistry we also confirmed that proinflammatory cytokines are produced by human β-islets is paralleled by improved functional β-cell mass (32). Exendin-4 protects β-cells from IL-1β-induced cells in vitro. We performed triple immunostaining for apoptosis by interfering with the JNK pathway (30).
activation and improvement of glucose responsiveness (29,39). This effect was observed in four out of six Studies designed to evaluate the effect of exenatide or other GLP-1 analogs in cytokine induced-apoptosis have human islet preparations, perhaps reflecting the quality and potency of the islet isolation. shown protection from both apoptosis and activation of JNK (9, 30) . We studied the effect of exenatide on JNK, Prior to transplantation, human islets are routinely cultured for up to 72 h (41) . Based on our results, we specup38, NF-κB and cJun activation and did not observe any alteration of the basal phosphorylation levels of these late that pretreatment of human islets with exenatide prior to transplantation could reduce the state of inflammation kinases. Collectively, these results indicate that although exenatide protect islets against the toxic effect of cytoand in turn improve transplantation outcome. PI-9 is a protein that plays a critical role in the surkines in vitro (9,30), it does not affect the expression of the kinases in culture.
vival of cells exposed to the attack of the immune system. PI-9 is unique for its ability to inhibit both In addition, exenatide activated STAT3 in human islets. This protein has been implicated in insulin sensitiinflammation and apoptosis. It also inhibits caspases-1 and -3 and thereby reduces the production of inflammazation (50), α-cell mass expansion (25) , and protection from cytokine-induced apoptosis (59) . Another importory cytokines (44, 68) . Expression of increasing levels of PI-9 in target cells might progressively inhibit the tant mediator in apoptosis is caspase-3, considered to be a central protein in the execution of apoptosis. Within immune surveillance by blocking natural killer cells (NKs) and cytotoxic T lymphocytes (CTLs) through the 24 h exenatide inhibited caspase-3 activation about 50%, when compared to controls. Furthermore, culturing inhibition of perforin/granzyme B as well as Fas/FasLmediated death pathways (18,42). Notably, elevation of human islets with exenatide improves islet glucoseinduced insulin secretion as assessed by dynamic perifu-PI-9 levels has been described into immune-privileged sites (8, 18) . Our results show that treatment with exenasion stimulation. These results are in agreement with previous studies showing that GLP-1 activation protects tide increased PI-9 expression in a dose-dependent and sustained manner. Both in human and mouse islets we islet cells against apoptosis via inhibition of caspase-3 Figure 5 . Insulin release after glucose and KCl challenge. Exenatide increases glucose induced insulin release in a concentration dependent manner. Whereas otherwise noted, glucose concentration is 3 mM. Islets are stimulated with 11 mM glucose and 25 mM KCl. Human islets were cultured for 48 h with the indicated increasing concentrations of exenatide. After washout incubation in the perifusion buffer not containing exenatide, islets were subject to a dynamic glucosestimulated insulin release assay (perifusion). Note that the same islet number was utilized for the assay and insulin concentration was corrected for DNA content. The figure shows a representative experiment out of six independent assays performed. found that exenatide induces a rapid and sustained be possible that binding of the exendin-9 to GLP-1R might be in part agonistic for some effects mediated increase in PI-9 content. PI-9 appeared as a very fast and quite potent agent because a 50% increase in protein through this receptor under special conditions. Further studies will be necessary to shed light on this topic. content was observed within 1 h (Fig. 6) . RT-PCR showed that after 48 h of treatment with exenatide the Notably, immunostaining with human islets of PI-9, insulin, and glucagon suggest that PI-9 is constitutively mRNA level of PI-9 was still 40% higher than in control mouse islets (data not shown). Exenatide is a better expressed in β-cells but not in α-cells (Fig. 7) . Exenatide-mediated PI-9 induction was mediated by mediator of PI-9 expression than GLP-1; it induces up to 25% more of PI-9 (Fig. 6C) . The antagonist exendincAMP, similarly to what has been previously reported for exenatide-mediated mitogenic effects in β-cells 9 partially inhibits the induction of PI-9 expression. Unexpectedly, exendin-9 by itself also mediates PI-9 (21,66) and for exenatide-mediated inhibition of chemokine (C-X-C motif) ligand (CXCL)10 (58), which has expression compared to control islets although not up to the extent induced by GLP-1 or exenatide. Interestingly, a role in insulitis in type 1 diabetes (15) . Importantly, exenatide also induced PI-9 upregulation in human islets in the same study reporting that exendin-9 is a potent antagonist at the GLP-1 receptor in insulin-producing after transplantation into immunodeficient animals, ruling out the possibility that it was an in vitro artifact and cells, the authors observed in long-term experiments a small agonistic activity of exendin-9 (37). Thus, it might confirming the relevance of this phenomenon in an . Data are representative of three independent experiments. One-way ANOVA was performed to determine statistically significant differences. *,**Differences between groups at p < 0.05. Figure 9 . Exenatide upregulates expression of PI-9 in human islet grafts explanted from nude mice. Human islets were transplanted under the kidney capsule of nude mice. Mice were treated intraperitoneally with either saline or exenatide (3 µg/day). Grafts were explanted after 24 h of treatment. Aliquots of the same human islet preparations (not transplanted) were used to determine baseline levels (Control). Samples were analyzed by RT-PCR (n = 4 grafts per group). *Statistical difference at p < 0.05 (one-way ANOVA).
experimental transplantation setting (Fig. 9) . Notably, may contribute to mitigate/block NK and CTL-induced cytotoxicity through the perforin/granzyme pathway and we used a continuous dose of exenatide in the in vivo experiments achieved by osmotic pump implantation.
the Fas/FasL pathway. Although not formally addressed in our study, it is conceivable that the observed PI-9 This was based on the consideration that the half-life of exenatide is estimated of 2.4 h and that metabolic rates upregulation by human islets after exposure to exenatide both in vitro and, importantly, after transplantation into in mice are higher than in humans and several drugs are required in higher doses to achieve their efficacy range immunodeficient animals, may represent a desirable phenomenon particularly in the context of islet transin this model. In fact, it has been estimated that degradation of exenatide by kidney membranes in mice was 15- plantation and autoimmunity. fold slower in human than in mouse (17 osmotic pump delivery would provide more efficient availability of the drug to assess its effect on transplanted human islets. REFERENCES Collectively, our study contributes to the elucidation human islets, which may reduce human islet graft immu-
